Review article · 2023 · Open access

Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials

Spyridon Siafis, Johannes Schneider‐Thoma, Tasnim Hamza, Irene Bighelli, Shimeng Dong, Wulf‐Peter Hansen, John M. Davis, Georgia Salanti, Stefan Leucht

BMJ Open, 13(2), e064504 · Published 1 February 2023 · DOI 10.1136/bmjopen-2022-064504

Open PDFView at the publisherCite this paper

In brief

“Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials” is a 2023 review article by Spyridon Siafis and 8 co-authors, published in BMJ Open. OpenAlex counts 2 citations as of 20 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at BMJ Open.

Citations
2
Most cited in
2024 (1)
Field-weighted impact
0.06
References
35
Authors
9

Abstract

INTRODUCTION: Guidelines recommend clozapine for treatment-resistant schizophrenia. However, meta-analysis of aggregate data (AD) did not demonstrate higher efficacy of clozapine compared with other second-generation antipsychotics but found substantial heterogeneity between trials and variation between participants in treatment effects. Therefore, we will conduct an individual participant data (IPD) meta-analysis to estimate the efficacy of clozapine compared with other second-generation antipsychotics while accounting for potentially important effect modifiers. METHODS AND ANALYSIS: In a systematic review, two reviewers will independently search Cochrane Schizophrenia Group's trial register (without restrictions in date, language or state of publication) and related reviews. We will include randomised controlled trials (RCTs) in participants with treatment-resistant schizophrenia comparing clozapine with other second-generation antipsychotics for at least 6 weeks. We will apply no restrictions in age, gender, origin, ethnicity or setting, but exclude open-label studies, studies from China, experimental studies and phase II of cross-over trials. IPD will be requested from trial authors and cross-check against published results. AD will be extracted in duplicate. Risk of bias will be assessed using Cochrane's Risk of Bias 2 tool.The primary outcome will be overall symptoms of schizophrenia.We will synthesise results using random-effects meta-analysis and meta-regression methods in a 3-level Bayesian model. The model combines IPD with AD when IPD is not available for all studies, and include participant, intervention and study design characteristics as potential effect modifiers. The effect size measures will be mean difference (or standardised mean difference when different scales were used). Confidence in the evidence will be assessed using GRADE. ETHICS AND DISSEMINATION: This project has been approved by the ethics commission of the Technical University of Munich (#612/21 S-NP). The results will be published open-access in a peer-review journal and a plain-language version of the results will be disseminated.If we need to amend this protocol, we will describe the change and give the rationale in a specific section in the resulting publication 'Changes with respect to the protocol'. SYSTEMATIC REVIEW REGISTRATION: PROSPERO (#CRD42021254986).

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Siafis, S., Schneider‐Thoma, J., Hamza, T., Bighelli, I., Dong, S., Hansen, W., Davis, J. M., Salanti, G., & Leucht, S. (2023). Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials. BMJ Open, 13(2), e064504. https://doi.org/10.1136/bmjopen-2022-064504

MLA 9

Siafis, Spyridon, et al. “Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials.” BMJ Open, vol. 13, no. 2, 2023, p. e064504. https://doi.org/10.1136/bmjopen-2022-064504.

Chicago

Siafis, Spyridon, Johannes Schneider‐Thoma, Tasnim Hamza, Irene Bighelli, Shimeng Dong, Wulf‐Peter Hansen, John M. Davis, Georgia Salanti, and Stefan Leucht. 2023. “Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials.” BMJ Open 13 (2): e064504. https://doi.org/10.1136/bmjopen-2022-064504.

Harvard

Siafis, S. et al. (2023) ‘Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials’, BMJ Open, 13(2), p. e064504. doi:10.1136/bmjopen-2022-064504.

IEEE

S. Siafis et al., “Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials,” BMJ Open, vol. 13, no. 2, p. e064504, 2023, doi: 10.1136/bmjopen-2022-064504.

BibTeX

@article{siafis2023efficacy,
  title     = {{Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials}},
  author    = {Siafis, Spyridon and Schneider‐Thoma, Johannes and Hamza, Tasnim and Bighelli, Irene and Dong, Shimeng and Hansen, Wulf‐Peter and Davis, John M. and Salanti, Georgia and Leucht, Stefan},
  journal   = {BMJ Open},
  year      = {2023},
  volume    = {13},
  number    = {2},
  pages     = {e064504},
  doi       = {10.1136/bmjopen-2022-064504},
  url       = {https://doi.org/10.1136/bmjopen-2022-064504}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • clozapine
  • atypical antipsychotics
  • treatment-resistant schizophrenia
  • antipsychotic efficacy
  • individual patient data meta-analysis
  • effect modifiers
  • symptom outcomes
  • Bayesian hierarchical model

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Siafis, S., Schneider‐Thoma, J., Hamza, T., Bighelli, I., Dong, S., Hansen, W., Davis, J. M., Salanti, G., & Leucht, S. (2023). Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials. BMJ Open, 13(2), e064504. https://doi.org/10.1136/bmjopen-2022-064504

How many times has this paper been cited?

2 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at BMJ Open: sign in and open the PDF from this page.

Who wrote this paper?

Spyridon Siafis, Johannes Schneider‐Thoma, Tasnim Hamza, Irene Bighelli, Shimeng Dong, Wulf‐Peter Hansen, John M. Davis, Georgia Salanti, Stefan Leucht.

What is the DOI of this paper?

10.1136/bmjopen-2022-064504, permanently at https://doi.org/10.1136/bmjopen-2022-064504. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.